Summary
Introduction
Dihydralazine is a widely used antihypertensive agent which acts by relaxing the smooth muscles of precapillary arterioles and thus decreases Correspondence: Dr Ingrid W. Reimann, Dr Margarete Fischer-Bosch-Institut fur Klinische Pharmakologie, Auerbachstrasse 1 12, 700 Stuttgart 50, Germany (FRG).
peripheral arteriolar resistance [ 1 I. The molecular mechanism of action of dihydralazine is not well understood at present. Prostaglandins (PG) are known to participate in the regulation of vascular reactivity and blood pressure. They may interfere by opposing the vasoconstrictor and antinatriuretic actions of the renin-angiotensin-aldosterone system [2, 31, by modulating the action and/or release of noradrenaline from vasoconstrictor nerves [41, by amplifying the effects of the kallikrein-kinin system [51 or by acting directly on vascular smooth muscles 161. The vasodilator P G (PGE,, PGI,, PGDd could act locally although it has been suggested that circulatory PGI, has a role as it (in contrast to the other PG) is not inactivated on passage through the pulmonary vascular bed [71.
It is possible that vasodilator PG could play a role in the action of dihydralazine. We have investigated their contribution by comparing the effects of dihydralazine before, and after, blockade of cyclo-oxygenase, the enzyme essential for P G synthesis. The study was carried out as an acute experiment, infusing both dihydralazine and the cyclo-oxygenase inhibitor diclofenac in order to avoid interference by sodium retention, a known effect of cyclo-oxygenase inhibitors given chronically.
Patients and methods

Patients
Four patients, two females and two males, aged 23, 40, 30 and 56 years, participated in this pilot study and gave written informed consent. All of them had had mild to moderate essential hypertension for 2-7 years, blood pressure values ranging from 160/110 to 210/130 mmHg, but were otherwise healthy and had normal renal function.
The patients were withdrawn from treatment in hospital and brought into sodium balance on 150 mmol of sodium/day. They all became normotensive with respect to systolic blood pressure; two patients had slightly elevated diastolic blood pressure values at the start of the study.
Study design
After having come into sodium balance the intravenous dose of dihydralazine required to reduce supine systolic blood pressure by 20 mmHg from control was determined for each individual in a pilot study several days before the acute treatment was started. In this initial study a solution containing 150 mg of dihydralazine as methanesulphonate (Nepresol, Ciba-Geigy) in 50 ml of saline was infused at rates of 2.7, 5-4, 8-1, 10.8 and 16.2 mg/h with an infusion pump. The infusion rates were increased in 30 min intervals. Blood pressure (method of Riva-Rocci, discontinuously) and pulse rate controls were done in 5-10 min intervals.
The acute study was performed in all patients according to the same regimen lasting from 07.00 hours to noon, in single-blind, randomized crossover fashion, with a 1 day interval between the 2 days of acute treatment.
At 09.00 hours indwelling catheters were placed into the cubital veins in both arms. A dose (75 mg) of diclofenac (Voltaren, Geigy), in 20 ml of saline, or placebo (saline) was injected 1 h before starting the infusion of dihydralazine, the individual, previously determined dose being used. Blood samples for determination of sodium, potassium and creatinine were taken 1 h afterwards by venepuncture from the forearm vein contralateral to the infused vein. At 10.00 hours a 2 h dihydralazine infusion was started, the infusion rates varying from individual to individual (between 0.045 and 0.090 ml/min). Blood samples for determination of the above-mentioned parameters were drawn at 30 min intervals during the infusion. Urine samples for determination of sodium, potassium, creatinine and PGE, were collected during the 2 h interval before the study (07.00-09.00 hours) and the 3 h interval (09.00 hours to noon) during the experiment.
Analyses
Sodium and potassium in plasma and urine were measured by flame photometry and creatinine by the Jaffi reaction with picric acid. Urinary PGE, values were determined by previously published methods [8; I. W. Reimann & J. C. Frolich, unpublished work].
Results
The results of this study are summarized in Table  1 ; because of the small number of patients no statistical data are given.
As can be seen from Table 1 the dihydralazine-induced effects on diastolic blood pressure heart rate, urine excretion rate and sodium clearance are impressively reduced, coincident with a marked depression in urinary PGE, excretion rate, which reflects an inhibition of renal cyclo-oxygenase activity [91 by diclofenac. The systolic blood pressure reduction by dihydralazine was less during the acute study compared with the pilot study, where a mean of -20 mmHg was attained. The influence of diclofenac on dihydralazine-induced reduction of systolic blood pressure is only a slight one. Urinary potassium output was not changed by either dihydralazine or by concomitant treatment with diclofenac.
Discussion
This study shows that the blood pressurelowering effect of dihydralazine was attenuated by diclofenac. The effect was most clearly visible with respect to the diastolic values; systolic values were less affected. The increase in heart rate by dihydralazine was also attenuated by diclofenac. Urinary PGE, tended to increase with dihydralazine whereas diclofenac caused 60% reduction.
The dihydralazine-induced changes in renal function (increases in urine flow rate and sodium clearance) are coincident with the renal effects of vasodilating P G and they were fully antagonized by concomitant treatment with the PG inhibitor diclofenac.
There are several ways by which PG could mediate the cardiovascular action of dihydralazine. Stimulation of PG biosynthesis would lead to increased amounts of locally acting or circulating vasodilator PG, which may cause a direct relaxation of vascular smooth muscles [61 or may amplify the vasodilating properties of the kallikrein-kinin system [5]. A further important mechanism could be modulation of sympathetic reflex activation. Hedqvist and co-workers have pointed out that P G might exert a prejunctional action on adrenergic neurotransmission; for example, PGE, inhibits vasoconstriction responses to nerve stimulation by inhibition of noradrenaline release [41. On the other hand PGI, had no effect on neurally induced transmitter release; its modulation of vasoconstrictor responses, at least to renal nerve stimulation, was interpreted as a postjunctional phenomenon [41. Taken together, locally formed vasodilating P G could modulate adrenergic neuroeffector transmission by a negative feedback mechanism 1101 in which pre-and post-junctional actions may be involved.
Renal renin release is regulated by cyclooxygenase-dependent mechanisms [2] as well as via the renal nerves and circulating catecholamines by both D-and a-adrenoceptors [for reviews see 2, 111. Enhancement of renin release after dihydralazine administration is a wellknown effect, attributed to increased reflex sympathetic activity [12] , but perhaps mediated by direct PG-dependent stimulation as well.
Investigations by Haeusler & Gerold [13] demonstrated increased levels of prostaglandinlike material in the blood of dogs during arterial hypotension induced by dihydralazine and Forster and co-workers 1141 were able to show enhanced PGI, biosynthesis in the aortas of spontaneously hypertensive rats after dihydralazine administration.
The results of the present study differ from those recently described by Campbell et af. [151, who investigated the effects of indomethacin on hydralazine-induced renin and catecholamine release in conscious rabbits. Even though indomethacin inhibited renal venous PGE, production by 56%, as well as hydralazine-induced tachycardia and increase in plasma renin activity by 24% and 75% respectively, it failed to alter significantly hydralazine-induced increases of plasma catecholamines. The hypotensive effect of hydralazine was augmented by 6%. These differences, besides pointing to species variation, show that several factors important for the regulation of blood pressure are affected by prostaglandin inhibition.
